Charles N. Mills bought $74.8M of Medline (MDLN)
Executed Dec 18 2025, disclosed Dec 22 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 22 2025), the stock returned +9.2% (delay-adjusted); from the execution session (Dec 18 2025), +15.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Charles N. Mills (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Medline Inc. (MDLN). Across 1 priced purchase filing, the average 21-session return was +15.7% from execution and +9.2% from disclosure (delay-adjusted; derived). The largest single filing was $74.8M of MDLN (2,579,310 sh across 2 lots, as filed), executed Dec 18 2025.
Healthcare · Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing ho…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→